Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
复制标题
DOI:
10.1016/j.celrep.2015.02.052
复制
发表时间:
2015-03-24
期刊:
影响因子:
8.8
通讯作者:
Degterev A
中科院分区:
文献类型:
--
作者:
Najjar M;Suebsuwong C;Ray SS;Thapa RJ;Maki JL;Nogusa S;Shah S;Saleh D;Gough PJ;Bertin J;Yuan J;Balachandran S;Cuny GD;Degterev A
RIPK1 and RIPK3, two closely related RIPK family members, have emerged as important regulators of pathologic cell death and inflammation. In the current work, we report that the Bcr-Abl inhibitor and anti-leukemia agent ponatinib is also a first-in-class dual inhibitor of RIPK1 and RIPK3. Ponatinib potently inhibited multiple paradigms of RIPK1- and RIPK3-dependent cell death and inflammatory TNFα gene transcription. We further describe design strategies that utilize the ponatinib scaffold to develop two classes of inhibitors (CS and PN series), each with greatly improved selectivity for RIPK1. In particular, we detail the development of PN10, a highly potent and selective ‘hybrid’ RIPK1 inhibitor, capturing the best properties of two different allosteric RIPK1 inhibitors, ponatinib and necrostatin-1. Finally, we show that RIPK1 inhibitors from both classes are powerful blockers of TNF-induced injury in vivo. Altogether, these findings outline promising candidate molecules and design approaches for targeting RIPK1/3-driven inflammatory pathologies.
登录
查看更多内容
影响因子:
3.7
作者:
McNamara CR;Ahuja R;Osafo-Addo AD;Barrows D;Kettenbach A;Skidan I;Teng X;Cuny GD;Gerber S;Degterev A
通讯作者:
Degterev A
影响因子:
3.7
作者:
Beard H;Cholleti A;Pearlman D;Sherman W;Loving KA
通讯作者:
Loving KA
影响因子:
9.8
作者:
Levinson NM;Kuchment O;Shen K;Young MA;Koldobskiy M;Karplus M;Cole PA;Kuriyan J
通讯作者:
Kuriyan J
影响因子:
9
作者:
通讯作者:
--
影响因子:
4.8
作者:
Kaiser, William J.;Sridharan, Haripriya;Mocarski, Edward S.
通讯作者:
Mocarski, Edward S.